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Abstract 
Review on del(18)(p11) in haematological 
malignancies, with data on the genes possibly 
involved. 
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Clinics and pathology 
del(18)(p11) is a very rare structural anomaly found 
only in 24 cases with onco-hematological disorders. 
This deletion has been observed in both myeloid 
(14 cases) and lymphoid (10 cases) malignancies 
and has been predominantly associated with a 
complex karyotype. In all cases 18p- is presented as 
a single copy in the karyotype. The anomaly was 
determined by conventional cytogenetic as terminal 
deletion with sub-band location of the breakpoint in 
18p11.2. Microarray comparative genome 
hybridization (aCGH) studies in patients with acute 
myeloid leukemia have demonstrated that the 
deleted segment in 18p could be also interstitial and 
variable in size as has been proven in other tumor 
associated deletions. Three submicroscopic deleted 
regions have been identified - 18p11.32-p11.31, 
18p11.23 and 18p11.22-p11.21 (Itzhar et al, 2011). 
Disease 
Acute Myeloid Leukemia (AML) 
Epidemiology 
del(18)(p11) is found in 9 cases ( 0.1% of all AML 
cases with an abnormal karyotype) (Alimena et al., 
1981; Brodeur et al., 1983; GFCH, 1990; Lawler et 
al., 1990; Mohamed et al., 1993; Davey et al., 1995; 
Krauter et al., 1998; Babicka et al., 2007; Kasyan et 
al., 2010) -  1 case  with M1 French-American-
British (FAB) phenotype, 2 cases with M2, 1 case 
with M3, 1 case with M4, 1 case with M6 and 3 
with AML, NOS (one diagnosed as therapy related 
AML).  
The sex ratio is significantly unbalanced, near 
M:F=3.5:1.  
The age is documented in 5 cases: 6 and 35 (M2), 
59 (M3), 42 (M4) and 61 (M6). 
Cytogenetics 
In 5 cases del(18)(p11) is found in complex 
karyotypes and in one as a sole anomaly. Three 
cases are with -5/del(5q), two with +8 and one case 
of each of the following well known 
rearrangements: -7; del(17p); t(8;21)(q22;q22); 
t(17;20)(q21;q11) in a M3 ( RARA not checked). In 
one case both arms of chromosome 18 are affected- 
der(18)del(18)(p11)del(18)(q21). In 3 cases 18p- is 
associated with sex chromosome abnormalities - 2 
with a loss of Y chromosome and one with 
del(X)(q26). 
Disease 
Other Myeloproliferative Disorders 
Epidemiology 
del(18)(p11) is described in  2 cases (one male and 
one female) with chronic myeloid leukemia (CML) 
(Ohyashiki et al., 1997; Sun et al,. 2011), 2 cases 
(males) with a myelodysplastic syndrome (Cerretini 
et al., 2002; Volkert et al., 2014) and one case 
(female) with primary myelofibrosis (PMF) 
involving a lymph node (Hu et al., 2009). 
del(18)(p11) Mitev L, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(12) 444 
 
Cytogenetics 
In 2 cases with MDS and one case with CML 
del(18)(p11) is associated with a complex 
karyotype,  in one case with CML it is a second 
event and in one case (with PMF) it is a sole 
anomaly.  
In the two cases with CML 18p- anomaly is present 
in additional deviating sub-clones (sidelines) and in 
one case with MDS in two clones with 
dic(17;20)(p11-12;q11) and dic(18;18)(p11;p11). 
Disease 
Acute Lymphoblastic Leukemia (ALL) 
Epidemiology 
del(18)(p11) is found in 8 cases with ALL (0.08% 
of all ALL cases with an abnormal karyotype) 
(Oshimura et al., 1977; Kanerva et al., 2002; van 
der Burg et al., 2002; Soulier et al., 2003; Karst et 
al., 2006; Shin et al., 2011; Schmiegelow et al., 
2012; Lundin et al., 2014).  
The sex ratio is significantly unbalanced, near 
M:F=1.7:1.  
The anomaly has been observed in young, as well 
as older patients (average age 22.6 years; range 5-
65). 
Cytogenetics 
In 5 cases del(18)(p11) is found in complex 
karyotypes and in 3 cases it is accompanied with 
second anomalies - der(21) in two cases and 
dup(18q)(q11q11) in one (unrelated clone). In 4 of 
the 5 cases with complex karyotypes 18p- is 
associated with one or more deletions including 6p-
, 9p-, 11q- and 12p- and in two cases with 
t(7;14)(p13;q32) and t(14;18)(q32;q21) (Shin et al., 
2011), respectively. 
Disease 
Follicular lymphoma (FL) 
Cytogenetics 
del(18)(p11) is reported in 2 cases with FL (Bosga-
Bouwer et al., 2003; Horsman et al., 2003). Both 
have hyperdiplpoid, highly complex karyotypes. 
Genetics 
A tumor suppressor gene(s) (TSG) important to the 
described hematological malignances may be is 
involved in the molecular pathogenesis of 
del(18)(p11).  
A number of TSG candidates are mapped in the 
deleted segment 18p11.2->18pter including PTPN2 
(18p11.21), LDLRAD4 (C18orf1) (18p11.21), 
RALBP1 (18p11.22), PPP4R1 (18p11.22), PTPRM 
(18p11.23), EPB41L3 (18p11.31), L3MBTL4 
(18p11.31), TGIF1 (18p11.31), ZEP161 (18p11.31) 
and SMCHD1 (18p11.32).   
Almost all are implicated in the pathogenesis of a 
variety of solid tumors, but there are several lines of 
data suggesting that four of them (PTPN2, PTPRM, 
TGIF1 and SMCHD1) could also have a role in 
leukogenesis and respectively may act as TSG in 
the hematopoietic system. 
Genes involved and 
proteins 
PTPN2 (protein tyrosine 
phosphatase, non-receptor type 2) 
Location 
18p11.21 
Protein 
PTPN2 (Tyrosine-protein phosphatase non-receptor 
type2) is a negative regulator of multiple signaling 
pathways, including IL2 (interleukin 2) mediated 
JAK2/STAT cascade and is inactivated by nonsense 
mutation in 5% and deleted in 6% of the cases with 
adult acute T-cell lymphoblastic leukemia (Kleppe 
et al., 2010). 
PTPRM (protein tyrosine 
phosphatase, receptor type M) 
Location 
18p11.23 
Protein 
PTPRM (Tyrosine-protein phosphatase, receptor 
type M) is targeted by aCGH within the deleted 
region 18p11.23 found in 17 cases with AML.  
The protein encoded by this gene is involved in 
cell-cell adhesion through hemophilic interactions. 
Hypermethylation of PTPRM in cases with ALL 
(Stevenson et al, 2013) and submicroscopic 
deletion of PTPRM in cases of adult T cell 
leukemia/lymphoma have been observed (Kataoka 
et al 2015). 
TGIF1 (TGFB induced factor 
homeobox 1) 
Location 
18p11.31 
Protein 
TGiF1 (TG-interacting factor 1) is targeted by 
aCGH within the deleted region 18p11.32p11.31 
found in 14 cases with AML.  
The protein encoded by this gene plays an essential 
role in the regulation of hematopoiesis inhibiting 
the signaling pathways of RA (retinoic acid) and 
TGFB1 (transforming growth factor beta) by 
transcriptional repression of SMAD2.  
It has been demonstrated that TGIF1 is a negative 
regulator of KMT2A (MLL)-rearranged AML 
(Willer et al, 2014). 
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SMCHD1 (structural maintenance of 
chromosomes flexible hinge domain 
containing 1) 
Location 
18p11.32 
Protein 
SMCHD1 (Structural maintenance of chromosome 
flexible hinge domain containing 1) is also targeted 
by aCGH within the region 18p11.32p11.31. 
This gene encodes a protein required for the 
maintenance of an X chromosome inactivation in 
females. It has been reported that SMCHD1 is 
associated with increased tumorigenesis in a mouse 
model.  
Global gene expressing profiling revealed that 
SMCHD1 normally repress genes activated by 
MLL- chimeric fusion proteins in leukemia (Leong 
et al, 2012).  
These data have suggested that the loss of 
SMCHD1 may cause hematological malignances of 
both cell lineage - myeloid and lymphoid. 
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